ID EM-2 AC CVCL_1196 SY EM2 DR BTO; BTO_0005904 DR CLO; CLO_0002922 DR EFO; EFO_0002176 DR CLDB; cl1164 DR ArrayExpress; E-MTAB-38 DR ArrayExpress; E-MTAB-783 DR ArrayExpress; E-MTAB-2770 DR ArrayExpress; E-MTAB-3610 DR ArrayExpress; E-MTAB-7721 DR ArrayExpress; E-MTAB-7722 DR BioSample; SAMN03472895 DR BioSample; SAMN10988561 DR cancercelllines; CVCL_1196 DR Cell_Model_Passport; SIDM01047 DR ChEMBL-Cells; CHEMBL3308889 DR ChEMBL-Targets; CHEMBL2366281 DR Cosmic; 787491 DR Cosmic; 906855 DR Cosmic; 994175 DR Cosmic; 1026572 DR Cosmic; 1078728 DR Cosmic; 1498416 DR Cosmic-CLP; 906855 DR DepMap; ACH-000295 DR DSMZ; ACC-135 DR DSMZCellDive; ACC-135 DR EGA; EGAS00001000978 DR GDSC; 906855 DR GEO; GSM887004 DR GEO; GSM888073 DR GEO; GSM1374474 DR GEO; GSM1669762 DR IARC_TP53; 340 DR IARC_TP53; 21326 DR IGRhCellID; EM2 DR LiGeA; CCLE_641 DR LINCS_LDP; LCL-1112 DR PharmacoDB; EM2_331_2019 DR PRIDE; PXD030304 DR Progenetix; CVCL_1196 DR PubChem_Cell_line; CVCL_1196 DR Wikidata; Q54832264 RX CelloPub=CLPUB00038; RX DOI=10.1016/B978-0-12-221970-2.50457-5; RX PubMed=3030532; RX PubMed=3332852; RX PubMed=3856862; RX PubMed=10071072; RX PubMed=10576511; RX PubMed=10637496; RX PubMed=20164919; RX PubMed=20215515; RX PubMed=20809971; RX PubMed=22460905; RX PubMed=25877200; RX PubMed=26589293; RX PubMed=27397505; RX PubMed=30285677; RX PubMed=30629668; RX PubMed=30894373; RX PubMed=31068700; RX PubMed=31160637; RX PubMed=35839778; CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: COSMIC cell lines project. CC Part of: LL-100 blood cancer cell line panel. CC Population: Caucasian. CC Doubling time: 2 days (CelloPub=CLPUB00038); ~35-40 hours (DSMZ=ACC-135). CC HLA typing: A*02:01,03:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293). CC HLA typing: A*02:01:01,03:01:01; B*07:02:01,44:02:01; C*05:01:01,07:02:01; DQB1*06:02:01,06:03:01; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-135). CC Microsatellite instability: Stable (MSS) (Sanger). CC Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=10071072; PubMed=10576511; PubMed=20809971; DepMap=ACH-000295). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP=906855; DepMap=ACH-000295). CC Omics: Genomics; DNA methylation analysis. CC Omics: Genomics; Whole exome sequencing. CC Omics: Phenotyping; Drug screening. CC Omics: Proteomics; Quantitative. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=0.62%; Native American=0%; East Asian, North=2.74%; East Asian, South=0%; South Asian=0%; European, North=68.28%; European, South=28.35% (PubMed=30894373). CC Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371. ST Source(s): Cosmic-CLP=906855; DSMZ=ACC-135; PubMed=25877200 ST Amelogenin: X ST CSF1PO: 10,12 ST D13S317: 9,12 ST D16S539: 11,12 ST D18S51: 13,15 ST D19S433: 15,16 ST D21S11: 30 ST D2S1338: 22,24 ST D3S1358: 14,16 ST D5S818: 8,12 ST D7S820: 10 ST D8S1179: 14 ST FGA: 21,22 ST Penta D: 13,14 ST Penta E: 7,16 ST TH01: 9.3 ST TPOX: 8,12 ST vWA: 14,17 DI NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive DI ORDO; Orphanet_521; Chronic myeloid leukemia OX NCBI_TaxID=9606; ! Homo sapiens (Human) OI CVCL_2033 ! EM-3 SX Female AG 5Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 41 // RX CelloPub=CLPUB00038; RA Keating A., Martin P.J., Bernstein I.D., Papayannopoulou T., RA Raskind W.H., Singer J.W.; RT "EM-2 and EM-3: two new Ph1+ myeloid cell lines."; RL (In book chapter) Normal and neoplastic hematopoiesis, UCLA symposia on molecular and cellular biology, New Series Vol. 9; Golde D.W., Marks P.M. (eds.); pp.513-520; Alan R. Liss; New York; USA (1983). // RX DOI=10.1016/B978-0-12-221970-2.50457-5; RA Drexler H.G.; RT "The leukemia-lymphoma cell line factsbook."; RL (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001). // RX PubMed=3030532; DOI=10.1016/0165-4608(87)90188-9; RA Raskind W.H., Disteche C.M., Keating A., Singer J.W.; RT "Correlation between cytogenetic and molecular findings in human RT chronic myelogenous leukemia lines EM-2 and EM-3."; RL Cancer Genet. Cytogenet. 25:271-284(1987). // RX PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9; RA Keating A.; RT "Ph positive CML cell lines."; RL Baillieres Clin. Haematol. 1:1021-1029(1987). // RX PubMed=3856862; DOI=10.1073/pnas.82.6.1810; PMCID=PMC397362; RA Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.; RT "Cell lines and clinical isolates derived from Ph1-positive chronic RT myelogenous leukemia patients express c-abl proteins with a common RT structural alteration."; RL Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985). // RX PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4; RA Drexler H.G., MacLeod R.A.F., Uphoff C.C.; RT "Leukemia cell lines: in vitro models for the study of Philadelphia RT chromosome-positive leukemia."; RL Leuk. Res. 23:207-215(1999). // RX PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9; RA Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.; RT "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines."; RL Leuk. Res. 23:1055-1060(1999). // RX PubMed=10637496; DOI=10.1038/sj.leu.2401604; RA Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H., RA Uphoff C.C.; RT "p53 alterations in human leukemia-lymphoma cell lines: in RT vitro artifact or prerequisite for cell immortalization?"; RL Leukemia 14:198-206(2000). // RX PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113; RA Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., RA Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., RA Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., RA Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.; RT "Signatures of mutation and selection in the cancer genome."; RL Nature 463:893-898(2010). // RX PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662; RA Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., RA Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., RA Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., RA Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., RA Haber D.A.; RT "A genome-wide screen for microdeletions reveals disruption of RT polarity complex genes in diverse human cancers."; RL Cancer Res. 70:2158-2164(2010). // RX PubMed=20809971; DOI=10.1186/1755-8166-3-15; PMCID=PMC2944125; RA Virgili A., Nacheva E.; RT "Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in RT chronic myeloid leukaemia: a FISH mapping study of CML patients and RT cell lines."; RL Mol. Cytogenet. 3:15.1-15.12(2010). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=25877200; DOI=10.1038/nature14397; RA Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., RA Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., RA Neve R.M.; RT "A resource for cell line authentication, annotation and quality RT control."; RL Nature 520:307-311(2015). // RX PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878; RA Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., RA Loewer M., Sahin U., Castle J.C.; RT "TCLP: an online cancer cell line catalogue integrating HLA type, RT predicted neo-epitopes, virus and gene expression."; RL Genome Med. 7:118.1-118.7(2015). // RX PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469; RA Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., RA Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., RA Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., RA Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., RA Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., RA Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., RA Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., RA Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.; RT "A landscape of pharmacogenomic interactions in cancer."; RL Cell 166:740-754(2016). // RX PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786; RA Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., RA Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., RA Yang H.H., Koeffler H.P.; RT "Profiling the B/T cell receptor repertoire of lymphocyte derived cell RT lines."; RL BMC Cancer 18:940.1-940.13(2018). // RX PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144; RA Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.; RT "Screening human cell lines for viral infections applying RNA-Seq data RT analysis."; RL PLoS ONE 14:e0210404.1-e0210404.22(2019). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646; RA Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., RA MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.; RT "The LL-100 panel: 100 cell lines for blood cancer studies."; RL Sci. Rep. 9:8218.1-8218.14(2019). // RX PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775; RA Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., RA Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., RA Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., RA Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., RA Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., RA Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.; RT "Pan-cancer proteomic map of 949 human cell lines."; RL Cancer Cell 40:835-849.e8(2022). //